CA2457840C - Hdl for the treatment of stroke and other ischemic conditions - Google Patents

Hdl for the treatment of stroke and other ischemic conditions Download PDF

Info

Publication number
CA2457840C
CA2457840C CA2457840A CA2457840A CA2457840C CA 2457840 C CA2457840 C CA 2457840C CA 2457840 A CA2457840 A CA 2457840A CA 2457840 A CA2457840 A CA 2457840A CA 2457840 C CA2457840 C CA 2457840C
Authority
CA
Canada
Prior art keywords
hdl
ischemia
administration
treatment
rhdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2457840A
Other languages
English (en)
French (fr)
Other versions
CA2457840A1 (en
Inventor
Alphonse Hubsch
Markus G. Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01120026A external-priority patent/EP1285662A1/en
Application filed by CSL Behring AG filed Critical CSL Behring AG
Publication of CA2457840A1 publication Critical patent/CA2457840A1/en
Application granted granted Critical
Publication of CA2457840C publication Critical patent/CA2457840C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
CA2457840A 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions Expired - Fee Related CA2457840C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31360501P 2001-08-20 2001-08-20
US60/313,605 2001-08-20
EP01120026A EP1285662A1 (en) 2001-08-20 2001-08-20 Reconstituted HDL for the treatment of stroke and ischemic conditions
EP01120026.8 2001-08-20
PCT/EP2002/009294 WO2003018047A2 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions

Publications (2)

Publication Number Publication Date
CA2457840A1 CA2457840A1 (en) 2003-03-06
CA2457840C true CA2457840C (en) 2011-10-11

Family

ID=26076691

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2457840A Expired - Fee Related CA2457840C (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions

Country Status (10)

Country Link
US (2) US20040266660A1 (https=)
EP (1) EP1425031B8 (https=)
JP (1) JP4284177B2 (https=)
AT (1) ATE396736T1 (https=)
AU (1) AU2002340825B2 (https=)
CA (1) CA2457840C (https=)
DE (1) DE60226881D1 (https=)
ES (1) ES2304452T3 (https=)
WO (1) WO2003018047A2 (https=)
ZA (1) ZA200401360B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0310100A (pt) * 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
JP5601750B2 (ja) * 2007-03-01 2014-10-08 シーエスエル、リミテッド 糖尿病患者の内皮機能異常の治療
CN102802618B (zh) 2009-06-25 2014-06-18 泰特拉有限公司 烟酸和米曲肼的治疗组合
JP2012532919A (ja) * 2009-07-16 2012-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 治療因子を含むｈｄｌおよび治療における使用
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
WO2012103163A2 (en) * 2011-01-25 2012-08-02 The Cleveland Clinic Foundation Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
EP2673296B1 (en) 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
AU2012236889A1 (en) * 2011-03-25 2013-05-09 The Trustees Of Columbia University In The City Of New York Pegylated human HDL particle and process for production thereof
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
WO2021191266A1 (en) 2020-03-25 2021-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hdl for the treatment of lung infections
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
US12599677B2 (en) 2020-10-05 2026-04-14 Northwestern University Targeted PH sensitive liposomes
KR20240018430A (ko) * 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3247588A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2026008645A1 (en) 2024-07-02 2026-01-08 Institut National de la Santé et de la Recherche Médicale Aerosolization of apolipoprotein a1 nanoparticles enriched with alpha-1-antitrypsin for the treatment of pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Also Published As

Publication number Publication date
ES2304452T3 (es) 2008-10-16
JP4284177B2 (ja) 2009-06-24
ZA200401360B (en) 2005-08-31
WO2003018047A2 (en) 2003-03-06
EP1425031B8 (en) 2008-09-03
DE60226881D1 (de) 2008-07-10
HK1064304A1 (en) 2005-01-28
AU2002340825B2 (en) 2007-07-05
JP2005501110A (ja) 2005-01-13
US20080108550A1 (en) 2008-05-08
CA2457840A1 (en) 2003-03-06
EP1425031B1 (en) 2008-05-28
US20040266660A1 (en) 2004-12-30
WO2003018047A3 (en) 2004-01-29
US7491693B2 (en) 2009-02-17
ATE396736T1 (de) 2008-06-15
EP1425031A2 (en) 2004-06-09

Similar Documents

Publication Publication Date Title
CA2457840C (en) Hdl for the treatment of stroke and other ischemic conditions
AU2002340825A1 (en) HDL for the treatment of stroke and other ischemic conditions
JPH05506034A (ja) アクチン結合性化合物の療法的使用
CN1248169A (zh) 含有3－环丙基甲氧基－n－(3,5－二氯－4－吡啶基)－4－(二氟甲氧基)苯甲酰胺和肺表面活性剂的治疗ards或irds的组合物
KR20230051721A (ko) 저혈압의 치료를 위한 안지오텐신 ii 단독 또는 조합
WO2022009081A1 (en) Drug for use against the novel coronavirus disease, covid-19
JP2024166198A (ja) 可溶性細胞外マトリックス組成物および血管内送達のための方法
White et al. An evaluation of the hemostatic effects of hydrophilic, alcohol, and lipophilic extracts of notoginseng
EP0588477A2 (en) Medicinal composition comprising TCF-II
EP1057489B1 (en) Use of midkine family proteins in the treatment of ischemic diseases
HK1064304B (en) Hdl for the treatment of stroke and other ischemic conditions
WO2003061680A3 (en) Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
NO321126B1 (no) Salt av et BPC (Body protection compound) "kroppsbeskyttelsesforbindelse"-peptid, omfattende 8 aminosyrerester, kompatibelt, lagringsstabilt, farmasoytisk preparat, diagnostisk lagringsstabilt preparat, anvendelser og fremgangsmater derav.
EP1285662A1 (en) Reconstituted HDL for the treatment of stroke and ischemic conditions
TWI311485B (en) Reconstituted hdl for the treatment of stroke and ischemic conditions
US8106009B2 (en) Pharmaceutical composition for preventing or treating ischemic diseases
WO1995007710A1 (en) Remedy for wound
JP4790195B2 (ja) 組織再生剤
RU2290194C1 (ru) Антитромботическое, антикоагулянтное, фибриндеполимеризационное, фибринолитическое средство
CA2635342A1 (en) Cytoprotective pharmaceutical combination which can be used in the prevention and treatment of systemic inflammatory response syndrome
HK1026145B (en) A composition for the treatment of irds and ards
JPWO1999027951A1 (ja) 静脈内持続投与用製剤
Waring Protein and lipid interactions in lung surfactant monolayers
AU2003201287A1 (en) Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
KR20160127017A (ko) 폐내 염증의 완화

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190820